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1. INTRODUCTION 
 
Prostate cancer (PCa) is the most frequently diagnosed cancer of men (899 000 new cases, 
13.6% of the total) and the fifth most common cancer overall. Nearly three quarters of the 
registered cases occur in developed countries (644 000 cases). Incidence rates of PCa vary by 
more than 25-fold worldwide, the highest rates being in Australia/New Zealand (104.2 per 
100,000) (1), Western and Northern Europe, Northern America. This is largely due to the 
widespread use of non-organized screening with prostate specific antigen (PSA) testing and 
subsequent biopsy in these regions. Incidence rates are relatively high in certain developing 
regions such as the Caribbean, South America and sub-Saharan Africa. With an estimated 258 
000 deaths in 2008, PCa is the sixth leading cause of death from cancer in men (6.1% of the 
total) (1). Because PSA testing has a much greater effect on incidence than on mortality, there 
is less variation in mortality rates worldwide (10-fold) than in incidence rates, and the number 
of deaths from PCa is almost the same in developed and developing regions. Mortality rates 
are generally high in predominantly black populations (Caribbean, 26.3 per 100,000 and sub-
Saharan Africa, Age-Standardized rates (ASRs): 18-19 per 100,000), very low in Asia (ASR 
2.5 per 100,000 in Eastern Asia for example) and intermediate in Europe and Oceania (1). 
PCa was the first most frequently diagnosed cancer of men in Sweden and it was the third in 
rank in Hungary after lung and colorectal cancer in 2008. The same ranking could be seen in 
the mortality data at this time (Figure 1). 
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Figure 1. The distribution of the incidence and mortality of malignant tumours in Hungary and in 
Sweden. 
 
 
A rapid increase of incidence of PCa has been observed in Sweden since the 1990s while the 
rate of mortality remained unchanged (Figure 2). During the same period, the increase of 
incidence in Hungary was less marked than in Sweden, and the mortality rate was lower and 
stable (1).  
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Figure 2.  Incidence and mortality rates of PCa in Sweden between 1960-2008.  
 
As a result of PSA screening, the majority of patients with PCa are diagnosed with potentially 
curable disease. Another consequence of screening is that the mean age of patients with this 
disease has diminished; PCa is no longer a disease of the elderly but is increasingly seen in 
middle aged men. Furthermore, screening leads to the down-staging of the disease with an 
increase in the number of organ-confined tumours, curable with radical prostatectomy (RP), a 
surgical treatment being increasingly offered (2). 
 
Treatment of PCa with RP, radiotherapy and anti-androgen therapy results in prolonged long 
term survival in patient with localized and androgen-dependent PCa. Various treatment 
options are currently available for localized disease, including RP, conformal (three-
dimensional) external beam radiation, brachytherapy and other types of local therapy (3,4). 
By contrast, hormone-refractory PCas are associated with disease relapse and poor survival.  
 
A better understanding of the biological heterogeneity of the disease and reliable prognostic 
markers are needed to plan the therapy adequately and avoid over- or under-treatment. 
Prognosis for patients with PCa may be defined as the prediction of future behaviour of 
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established malignancy, either in the absence of or after the application of therapy (5). Factors 
associated with outcome may be divided into two categories: 
1. Prognostic factors: those that predict relapse or progression independently of future 
treatment effects. 
2. Predictive factors: those that predict response or resistance to a specific treatment. 
Currently, there are no predictive factors or markers utilized in PCa. For example, unlike 
breast carcinoma oestrogen receptor status, which can be used to predict response to hormonal 
treatment with tamoxifen, androgen receptor status in prostatic carcinoma does not predict 
response to hormonal therapy.  Here, we briefly focus on prognostic factors, with 
stratification into categories of established factors recommended for routine reporting 
(category I), factors with promise or recommended despite incomplete data (category II), and 
factors that are not currently recommended due to insufficient evidence (category III) (Table 
1.) (6,7). 
  
Category I: Recommended for routine reporting (7)   
TNM based stage 
Histological grade (Gleason) 
Surgical margin status 
Perioperative serum PSA 
  
Category II: Factors with promise or recommended despite incomplete data  
DNA ploidy 
Histologic type 
Tumour amount in needle biopsy tissue  
Tumour amount in RP specimens (correlates with extracapsular disease) 
  
Category III: Not recommended due to insufficient evidence  
Genetic markers 
Neuroendocrine markers 
Proliferation markers, apoptosis 
Perineural invasion 
Vascular/lymphatic invasion 
Microvessel density 
Nuclear morphometry 
Androgen receptors 
Age 
 
Table 1.  Prognostic factors for prostate cancer: College of American Pathologists (CAP) and World 
Health Organization (WHO) (6) 
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Category I histopathological factors include pathologic stage and surgical margin status of 
radical prostatectomy specimens, and Gleason histological grade in all prostatic tissue 
samples. The best established prognostic parameter, the Gleason score is a widely accepted 
scoring system, the prognostic significance of which has been repeatedly proven (8), but it is 
also subject to considerable inter-observer variability, indicating the need for additional or 
alternative prognostic parameters.  
Category II factors that are recommended for reporting include histologic subtypes of PCa 
and tumour amount in needle biopsy and RP specimens. The tumour amount in needle biopsy 
tissue may be reported in quantities such as the number of positive cores out of total number 
of cores, total length (mm) of tumour in all cores, greatest percentage of a single core 
involved by carcinoma, and total or overall percentage of biopsy tissue involvement (which 
can be assessed by simple visual inspection). Data exist to suggest that it may be relevant to 
report more than one measure of tumour extent in needle biopsy tissue (9,10). For RP 
specimens, it has been recommended to report tumour size as a percentage of cancer in the 
prostate (6) Additionally, one could measure size of a dominant nodule in two dimensions and 
indicate the number of blocks involved by tumour over the total number of blocks submitted 
(11). DNA ploidy was also put into category II, but currently it is felt that the data are not 
compelling enough to warrant its routine use (6). The probability of extracapsular disease 
most likely correlates with increasing tumour volume (12). The presence of extracapsular 
extension (ECE) in RP has been shown to have a significant negative impact on both 
biochemical and clinical failure rates (13). Therefore, accurate prediction of ECE is crucial 
when planning adequate treatment. Many predictive models using different preoperative 
parameters have been developed to promote this process (14-16). Number of positive 
(tumour-containing) biopsies and percent of cores containing cancer in prostate biopsy may 
be useful clinical parameters in identifying patients at high risk for ECE (17,18).  
Category III factors are not currently recommended for reporting due to insufficient evidence. 
 
The prognostic significance of ductal differentiation in PCa was shown in a number of recent 
studies, indicating that tumours exhibiting this feature are more aggressive than their 
conventional acinar counterparts (19-23). Ductal adenocarcinoma of the prostate (DAP) is 
rare in its pure form and accounts for 0.4–1% of PCas (24), but focal ductal differentiation in 
common acinar PCa is observed in up to 5% of radical prostatectomy specimens (25). The 
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proportion of tumour showing ductal differentiation that confers a prognostic difference 
remains controversial, but it is becoming more and more evident that identifying ductal 
differentiation in PCa and delineating these cases from pure acinar adenocarcinoma of the 
prostate (AAP) is an essential diagnostic task (19-21). 
The role of immunohistochemistry in the diagnosis, differential diagnosis and prognostication 
of PCa is well documented in the literature, although it is mainly limited to prove the 
infiltrative nature of the lesions and/or their prostatic origin (26-28). The role of 
immunohistochemical markers in distinguishing different subtypes of PCa is a less explored 
area. Some reports indicate that neuroendocrine differentiation (NED) in the tumour is a 
significant prognostic parameter associated with shortened survival after endocrine therapy 
(29-31). A number of studies have analysed Ki67, p53, or bcl-2 expression in PCa, mostly in 
the context of prognosis (32-34). DAP expressing PSA and prostate-specific acid phosphatase 
(PSAP) may also show residual staining for high molecular weight cytokeratins and p63, and 
70% express alpha-methylacyl-CoA racemase (AMACR) (24). These immunohistochemical 
features are, however, very similar to those in AAP, and are of no diagnostic value in 
distinguishing tumours showing ductal differentiation from pure AAP.  
Our department’s experience with large format thick histology sections (subgross, “three 
dimensional” /3D/ pathology) of breast tissue during the past two decades has confirmed the 
ability of this technique to reliably differentiate between acinar (lobular) and ductal structural 
components of normal and pathologic breast tissue (35-37). Although the subgross (3D) 
histology technique has been used to study diseases of the prostate (38), we have found no 
reports using this technique to determine the ductal or acinar origin or differentiation of 
prostate cancer. Having to distinguish DAP from AAP, we studied 3D thick section histology 
of prostatectomy specimens in addition to reviewing all the archived standard histological 
material. 
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2. AIMS 
 
The aims of the thesis are as follows: 
 
2.1 to evaluate whether patients with PCa exhibiting ductal differentiation (DAP) have an 
unfavourable prognosis compared to those with pure AAP;  
 
2.2 to evaluate the expression of nine immunohistochemical markers as prognostic predictors 
and their value in delineating carcinomas with and without ductal differentiation; 
 
2.3 to refine the histological methodology for discriminating between DAP and AAP and 
explore whether these results have any therapeutic consequence; 
 
2.4 to evaluate the clinical utility of transrectal ultrasound-guided systematic sextant or octant 
biopsies in the prediction of ECE at RP;  
 
2.5 to find a useful combination of prognostic parameters in planning adequate therapy.  
 
 
3. PATIENTS AND METHODS  
 
3.1 Study population 
 
The study population consisted of 110 patients treated with RP at Falun Central Hospital, 
Sweden, between January 2000 and December 2006. In 21 of these cases bilateral pelvic 
lymphadenectomy was also performed. Each patient underwent preoperative examinations 
according to a standardized protocol for preoperative disease staging. All PCas were 
considered to be organ-confined at the time of RP.  
The following additional information was collected and analysed for this study: preoperative, 
postoperative and most recent serum PSA values, the adjuvant therapeutic regimens used, 
including hormone therapy, total androgen blockade, administration of radiotherapy and/or 
chemotherapy. Recurrence of the disease in this study was defined as histologically proven 
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local recurrence, loco-regional lymph node recurrence, development of distant metastases or 
biochemical recurrence (PSA level ≥ 0.2 ng/ml) (39).  
 
In an earlier phase of the study (January 2000- August 2005) we analysed 84 cases with 
ultrasound-directed systematic sextant (three biopsies per side; i.e. apex mid gland, base) 
biopsies in 60 cases and systematic octant (four biopsies per side; ie, apex, mid-lateral and 
mid-medial gland, base) biopsies in 24 cases. 
 
3.2 Histological examination 
 
The prostatectomy specimens were histologically evaluated using multi-level large-format 
whole-mount cross-sections over the entire specimen (3 to 8 large-format blocks per case). 
Our large-section histology technique employs standard 10x8 cm object glasses while the size 
of the paraffin blocks is adjusted to the size of the prostatectomy specimens. This enables 
assessment of tumour multifocality, individual lesion size, capsular involvement (ECE) and 
also involvement of the seminal vesicles, which are included with the entire prostate gland on 
the sections (Figure 3). The complete material (84 preoperative biopsies and 110 
prostatectomy specimens) was retrospectively reviewed. 
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Figure 3. Large-section histology image of a prostate slice with three positive core biopsies (top row) 
and three negative cores (lower row).  
 
Histological variables obtained from the prostatectomy specimens included histological 
tumour type (DAP or AAP), Gleason score, size measurement of the excised prostate and of 
the individual tumour foci, determination of the number of tumour foci, evaluation of the 
surgical margins, presence of ECE, vascular invasion, seminal vesicle invasion and 
description of the presence or absence of high-grade prostatic intraepithelial neoplasia (PIN).  
Ductal differentiation in the tumours was established on the basis of cellular characteristics 
and histological growth patterns, as described in the literature (40). The ductal parts of the 
tumour were composed of tall columnar cells (in contrast to cuboidal cells of the acinar 
cancers). The following growth patterns were regarded as typical of ductal differentiation: 
papillary, cribriform, and solid. Typical images illustrating the morphological criteria are 
shown in Figure 4. 
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Figure 4. The basic growth patterns in acinar (A) and ductal (cribriform [B], papillary and PIN-like 
[C], and solid [D]) prostate cancers (H&E 100X). Inserts with high power magnification details from 
the same tumours. 
 
Each case was analysed using a subgross, 1,500 micron thick 3D section technique: the 
paraffin block was melted in an incubator, the specimen was then placed into a series of 
xylene baths over a 24-hr period in order to complete the deparaffinization. After rehydration 
the tissue was stained with Harris haematoxylin and immersed in methyl salicylate for 
clarification. Low-power stereoscopic microscopy (5-10X magnification) was used to view 
the specimen while immersed in methyl salicylate (37). 
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Morphological criteria for evidencing ductal differentiation within a tumour in large format 
thick (3D) sections were: presence of large contorted cancer-filled ducts found in the 
periurethral or, unusually, in subcapsular location, associated with or in close proximity to the 
acinar part of the cancer; or presence of innumerable duct-like structures observed in large 
areas of the prostate, within the tumour and also in the adipose tissue surrounding the prostate 
(a rare finding). Typical cases of DAP and AAP are illustrated in Figure 5.  
Pure DAP and mixed ductal-acinar carcinomas were grouped together (they appear as DAP 
through the text). The extent of ductal differentiation within the tumour was not analysed. 
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Figure 5. Thick large-format (3D) histology section of a prostatectomy specimen (a); the 
corresponding two-dimensional (2D) large-format slide (b); comedo growth pattern in DAP in 3D (c) 
and 2D (d) histology; papillary DAP in 3D (e) and 2D (f) histology; pure cribriform growth pattern in 
DAP in 3D (g) and 2D (h) histology; AAP for comparison, 3D (i) and 2D (j) histology. 
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3.3 Immunohistochemistry  
 
Tissue microarray (TMA) blocks were constructed using archival formalin-fixed, paraffin-
embedded RP specimens from all 110 patients. Two 2 mm cores were taken from the area of 
the tumour showing the predominant Gleason pattern of the invasive cancer or from the ductal 
area, if present. Sections of 3.5 m were cut from the TMA blocks. The TMA slides were 
immunostained in the Ventana autostainer (Ventana Benchmark XT and Ultra) using Ventana 
UltraView DAB (760-500). The Ventana stainer uses a multimer cocktail of goat anti-rabbit 
and goat anti-mouse for the detection system, and horseradish peroxidase conjugate for the 
visualization of DAB solution. The slides were incubated with diaminobenzidine (DAB) as 
the chromogene for 10 minutes then counterstained with haematoxylin (Ventana 760-2021) 
and Bluing Reagent (760-2037) for 4 min. Slides were washed in hot tap water with detergent 
(YES) then washed in distilled water for 5 min, dehydrated through graded alcohols to xylene 
baths, and mounted in Pertex organic mounting medium (Histolab, Gothenburg, Sweden). The 
primary antibodies used are listed in Table 2. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 2. List of primary antibodies used in the present study and the basic technical parameters.  
(Inst.: Instrument; CC1: antigen retrieval solution, type 1; CC2: antigen retrieval solution, type 2; NE: neuroendocrine; RTU: ready to use (prediluted);  
XT: Ventana Bench Mark XT immunohistochemistry instrument; Ultra: Ventana Bench Mark Ultra immunohistochemistry instrument) 
Antibody Major 
function 
Ref. 
number 
Clone  Species Dilution Antigen retrieval Source Inst. 
Ki-67  
lot:00062416 
Proliferation M7240 MIB-1 mouse 1:100 CC1 mild 30 min DAKO XT 
p53  
lot:668526 
Tumour 
suppression 
800-2912 DO-7 mouse RTU CC1 mild 30 min Ventana XT 
p16   
lot:H2109 
Tumour 
suppression 
SC-1207 - rabbit 
poly 
1:25 CC2 mild 36 min Santa 
Cruz 
Ultra 
p27  
lot:038(501) 
Tumour 
suppression 
M7203 SX53G
8 
mouse 1:25 CC1 mild 30 min DAKO XT 
Cox-2  
lot:00034 
Inflammation
, decreased 
apoptosis 
M3617 CX-
294 
mouse 1:50 CC1 mild 30 min 
+amplifying 
DAKO XT 
EGFR 
Lot: 00038049 
Proliferation M7239 - mouse 1.50 Protease1; 8 min DAKO XT 
Tenascin-C  
lot:0129A 
Matrix 
protein 
M0636 DAKO-
TN2 
mouse 1:50 Protease1; 8 min DAKO XT 
Chromogranine A 
lot:00011085 
NE marker M0869 DAKO-
A3 
mouse 1:1500 CC1 mild 30 min DAKO XT 
bcl-2  
lot:29108 
Increased 
apoptosis 
760-4240 124 mouse RTU CC2 mild 36 min 
+amplifying 
Ventana Ultra 
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All biopsies were evaluated with all antibodies. The percentage of tumour cell nuclei stained 
for Ki-67, p53, p16, p27, and bcl-2 were counted, and a cut-off value of 10% used to 
distinguish high- and low-expression cases. Chromogranine A expression was estimated using 
a semi-quantitative scoring system based on the number of chromogranine A positive cells in 
a “hot spot” area at 400 × magnification (0, negative; 1, 1–4 positive cells; 2, 5–19 cells; and 
3, staining in ≥20 cells). For Cox-2 the intensity of staining was estimated on a four-grade 
scale (0, absent; 1, weak; 2, moderate; and 3, strong). The staining intensity of tenascin C was 
assessed in both the stromal and periglandular areas (0, negative/normal staining; 1, 
weak/moderate staining; and 2, strong staining). Membranous immunoreactivity for 
epidermal growth factor receptor (EGFR) was categorized as undetectable (0), staining in less 
than 10% of tumour cells or as faint incomplete membrane staining in more than 10% of the 
tumour cells (1), weak to moderate, complete membrane staining in more than 10% of tumour 
cells (2), and intense complete membrane staining in more than 10% of tumour cells (3).  
 
3.4 Statistical analysis of the biomarker study 
 
The Chi-square test was used to assess the relationship of each biomarker to AAP and to 
DAP. The Fisher’s exact test was adopted, if the expected number of cases was less than 5. 
We also adopted the logistic regression model to estimate the odds ratios for each biomarker 
indicating DAP or AAP. The biomarkers shown to be significant in univariate analysis were 
evaluated in multivariate logistic regression in order to select the most significant biomarkers. 
The receiver-operating characteristic (ROC) curve was used to assess the discriminatory 
power of the three selected biomarkers (see later). The area under the curve (AUC) and its 
95% confidence interval were calculated according to Hanley (41). We tested the preoperative 
discriminative ability of three selected biomarkers to predict the risk of DAP among 24 
preoperative core biopsy samples from 110 cases and adjusted to the baseline risk of the 24 
test cases on eight different combinations of the three biomarkers. The entire material was 
followed up until August 31, 2010, giving a mean follow-up time of 5.1 years (60.9 months, 
standard deviation 21.2).  
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3.5 Statistical analysis of the ECE study 
 
The presence or absence of ECE, defined as penetration of the tumour beyond the capsule of 
the prostate, was correlated with the number of positive (tumour-containing) needle biopsies 
(none, one, two or three) using Chi-square test. The data were analysed in two different ways 
to determine the value of at least sextant needle biopsies in the prediction of ECE. First, a 
side-for-side analysis was performed in the 168 prostatic sides (84 cases) available in this 
series. The number of positive needle biopsies on each side (none, one, two or three) was 
correlated with the presence or absence of ECE at RP. Secondly, for each patient, a dominant-
side analysis was performed to assess the utility of systematic needle biopsies in predicting 
ECE in the side containing the greatest tumour volume. In this analysis, the number of 
positive needle biopsies (one, two or three) in the dominant lobe was correlated with the 
presence or absence of extracapsular disease. In these cases we calculated the sensitivity, 
specificity, and the negative and positive predictive values of the number of involved 
preoperative core biopsies in predicting ECE.  
The preoperative PSA levels as well as the biopsy Gleason score was also registered in every 
case. PSA levels higher than 10 ng/ml and Gleason score higher or equal to 7 were regarded 
as high-risk parameters and were also tested as individual parameters and in combination with 
the number of positive cores. 
 
3.6 Ethics  
 
The study was approved by the Regional Ethical Committee of the Uppsala-Örebro Health 
Care Region, Sweden (Dnr:2010/087). All surviving patients gave written consent for the use 
of the prostate histology samples for research purposes. 
 
4. RESULTS  
 
4.1. Comparison of DAP with AAP 
 
The subgross (3D) histology specimens together with routine large format histology slides 
demonstrated focal ductal differentiation in 12 cancers (mixed ductal-acinar cases) and 
evidenced one case of pure DAP. The remaining 97 cases were AAPs. Table 3 summarizes 
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the clinical and pathological characteristics of cases of pure AAPs (97/110;88%) and DAPs 
(13/110;12%). 
Parameter Acinar 
adenocarcinoma 
(AAP) 
Ductal/mixed 
ductal-acinar 
adenocarcinoma 
(DAP) 
p-value 
Number of cases  97/110 (88%) 13/110 (12%)  
Mean patient age (years) 61.95 (38-78) 63.08 (52-69) 0.5793 
Positive digital rectal examination 35/97 (36%) 10/13 (77%) 0.0049 
Size (mm) of prostate measured by transrectal 
ultrasound 
28.4 (15-102) 34.6 (22-60) 0.0021 
Preoperative PSA level, ng/ml  8.04 (2.1-26) 8.97 (3.7-19) 0.4869 
Postoperative PSA level  
≥ 0.2 ng/ml  
0.49 (0.22-1) 0.75 (0.20-1.30) 0.4143 
Number of pT2 cases  71/97 (73%) 2/13 (15%) <0.0001* 
Number of pT3a and pT3b cases  23/97 (24%) 8/13 (61%)  
Number of pT3c cases  3/97 (3%) 2/13 (15 %)  
Number of pT4a cases  0/97 1/13 (8%)  
Cases with a single tumour focus  5/97 (5%) 1/13 (8%) 0.3459* 
Cases with 2-4 tumour foci  69/97 (71%) 7/13 (54%)  
Cases with >5 tumour foci  23/97 (24%) 5/13 (38%)  
Cases with the largest tumour focus 1-19 mm  55/97 (56%) 3/13 (23%) 0.0020* 
Cases with the largest tumour focus 20-39 mm 42/97 (43%) 8/13 (62%)  
Cases with the largest tumour focus ≥40 mm 0/97 2/13 (15%)  
Disease extent, mm  36.49 (10-53) 41.54 (21-70) 0.0605 
Presence of high grade PIN 52/97 (54%) 12/13 (92%) 0.0079 
Cases with Gleason score <6  13/97 (14%) 0/13 <0.0001* 
Cases with Gleason score =6  42/97 (43%) 0/13  
Cases with Gleason score =7  35/97 (36%) 8/13 (62%)  
Cases with Gleason score >7  7/97 (7%) 5/13 (38%)  
Cases with a positive surgical margin  16/97 (16%) 6/13 (46%) 0.0219* 
Cases with extracapsular extension  25/97 (26%) 11/13 (84%) <0.0001* 
Cases with vascular invasion 6/97 (6%) 5/13 (38%) 0.0033* 
Cases with seminal vesicle infiltration  3/97 (3%) 3/13 (23%) 0.0213* 
Cases with biochemical/local recurrence  11/97 (11%) 8/13 (62%) <0.0001* 
Cases with locoregional lymph node metastases  0/97 2/13 (15%)  
Cases with distant metastases  0/97 3/13 (23%)  
Cases with prostate cancer death  0/97 1/13 (8%) 0.1508* 
Cases with death from other disease  3/97 (3%) 0/13  
Cases with adjuvant radiotherapy  14/97 (14%) 6/13 (46%) 0.0020* 
Cases with adjuvant hormonal therapy  4/97 (4%) 4/13 (31%) 0.0109* 
Cases with adjuvant total androgen blockage  0/97 3/13 (23%) 0.0013* 
Cases with adjuvant chemotherapy  0/97 1/13 (8%) 0.1182* 
 
Table 3. The clinical and pathological characteristics of the prostate cancer patients according to the 
presence or absence of a ductal component. Data are shown as n/N (%) or mean (range). * Fisher exact 
test 
  
29 
 
The DAP cases had a significantly greater frequency of the following parameters: positive 
digital rectal examination (p=0.0049), mean prostate size measured by transrectal ultrasound 
(p=0.0021), pT3a and more advanced cancers (p<0.0001), largest tumour focus >20 mm 
(p=0.0020), high grade PIN (p=0.0079), Gleason score ≥7 (p<0.0001), positive surgical 
margin (p=0.0219), ECE (p<0.0001), vascular invasion (p=0.0033), seminal vesicle 
infiltration (p=0.0213), biochemical/local recurrence, regional lymph node metastases, distant 
metastases (p<0.0001). The AAP cases had a significantly greater frequency of the following 
parameters: case frequency, pT1 and pT2 cases (p<0.0001), largest tumour focus <20 mm 
(p=0.0020) and Gleason score ≤6 (p<0.0001). There was no statistically significant difference 
in the patients' age at the time of prostatectomy, preoperative and postoperative PSA levels, 
and number of tumour foci or disease extent. 
 
Although all of the cases were clinically organ-confined at the time of RP, histologic 
examination confirmed that only 15% (2/13) of the DAP cases and 73% (71/97) of the AAP 
cases were organ confined. Of the 21/110 patients who were selected for bilateral pelvic 
lymphadenectomy, metastases were found in two, both of which were DAP cases. 
The outcome measures were all consistently poorer for DAP. During the average follow-up 
time of 5.1 years (range 4-10 years) all 13 DAP cases had evidence of disease progression: 
biochemical or local recurrence in 8 cases, distant metastases in 3 cases (one of whom died of 
the disease), lymph node metastases in 2 cases. In contrast, there was no evidence of disease 
progression in 86 (89%) of the 97 AAP cases. Disease progression was limited to biochemical 
recurrence only in the remaining 11 (11%) of these 97 cases, all 11 of which had a 
considerable tumour burden, with the largest tumour focus measuring at least 25 mm or being 
extensively multifocal. Among the 97 AAP cases, three patients died of unrelated causes 
during the follow-up period. 
 
4.2 Analysis of potential biomarkers of poor prognosis 
 
Table 4 shows the unadjusted and adjusted odds ratios for the ability of biomarkers to 
discriminate PC of acinar versus ductal origin in the total prostatectomy specimens.  
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Table 4. Unadjusted and adjusted odds ratios of immunohistochemical markers to distinguish pure 
acinar adenocarcinoma (AAP) of the prostate from ductal/mixed ductal-acinar type adenocarcinoma 
(DAP) of the prostate on the basis of 110 total prostatectomy specimens. *p value<0.001; + Exact 
method  
 
 
 
Biomarkers 
AAP 
No.(%) 
DAP 
No.(%) 
Unadjusted 
Odds Ratio 
Univariate 
95% CI 
Adjusted 
Odds 
Ratio 
Multivariate 
95% CI 
Ki67        
1-9% 71(94.7) 4 (5.4) 1    
≥10% 25 (73.5) 9 (26.5) 6.39 (1.81-22.59)*   
Chromogranine A        
Neg or <4 cells 78 (95.1) 4 (4.9) 1  1  
≥5 cells 18 (66.7) 9 (33.3) 9.75 (2.7-35.22) * 11.56 (2.04-65.31) 
Tenascin stroma        
Normal/weak 91(90.1) 10 (9.9) 1    
Moderate/strong 5 (62.5) 3 (37.5) 5.46 (1.13-26.33) *   
Tenascin 
Periglandular    
      
Normal 24 (100) 0 (0) 1    
Weak/moderate/strong 72 (84.7) 13 (15.3) 4.35+ (1.05-17.02) +   
EGFR       
10%membrane 
staining       
>=10%incomplete  
membrane staining 
92 (92.9) 7 (7.1) 1  1  
≥10% weak, moderate 
/ strong membrane 
staining 
5 (45.4) 6 (54.6) 15.77 (3.84-64.84) 11.25 (1.71-74.10) 
p53        
Neg/≤9% 85 (96.6) 3 (3.4) 1  1  
≥10% 12 (54.6) 10 (45.5) 23.61 (5.86-98.15) * 20.83 (3.71-116.94) 
p27        
Neg. or <=9% 68(88.3) 9(11.7) 1    
>=10% 28(87.5) 4(12.5) 1.08 (0.31-3.8)   
Cox-2       
Neg./Weak 75(90.4) 8(9.6) 1    
Moderate/Strong 21(80.8) 5(19.3) 2.23 (0.66-7.54)   
p16       
Neg/<=9% 53(93.0) 4(7.0) 1    
>=10% 44(83.0) 9(17.0) 2.71 (0.78-9.4)   
bcl-2       
 Neg/<=9% 94(89.5) 11(10.5) 1    
 >=10% 3(60) 2(40) 5.70 (0.86-37.9)   
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According to the previously described criteria, 26% (25/97) of AAP cases expressed Ki67 in 
10 percent or more of tumour cell nuclei, 18% (18/97) were chromogranine A positive, 5% 
(5/97) EGFR positive, 12% (12/97) p53 positive, 5% (5/97) expressed tenascin C in the 
tumour stroma, and 74% (72/97) showed periglandular tenascin C overexpression. The 
corresponding numbers for DAP were 69% (9/13), 69% (9/13), 46% (6/13), 77% (10/13), 
23% (3/13), and 100% (13/13), respectively. No statistically significant differences were seen 
in p27, cox-2, p16 and bcl-2 expressions.  
At multivariate (adjusted) analysis, three of the biomarkers studied provided the most 
significant discriminatory power: 12-fold for Chromogranine A (aOR=11.56; 95% CI:2.04-
65.38),  11-fold for EGFR (aOR=11.25; 95% CI:1.71-74.10), 21-fold for p53 percentage 
(aOR=20.83; 95% CI:3.71-116.94). Typical reactions in DAP and AAP cases are illustrated in 
Figure 6. A combination of these three biomarkers made it possible to distinguish between 
the DAP and AAP cases with an accuracy of 94% (AUC 0.94; 95% CI: 0.88-0.99).  
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Figure 6. Immunohistochemical p53 expression: absent in AAP (a), present in DAP (b); 
chromogranine A expression: few positively stained cells in AAP (c), numerous in DAP(d); EGFR 
expression absent in the AAP, present in the normal glands (e), and present in DAP (f).  
 
Table 5 demonstrates the results of testing the predictive value of the three selected 
biomarkers (Chromogranine A, EGFR, and p53 percentage) on the preoperative core biopsy 
tissue samples of 12 known DAP (each contained a characteristic pattern that resembled the 
ductal component) and 12 known AAP cases. The risk for a case being DAP increased with 
the number of positive biomarkers, being almost 100% for patients with three, followed by 
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91% to 95% for those with any two, 46% to 61% for those with any single biomarker, and 7% 
for those with no demonstrable biomarker positivity. We also confirmed that there was no 
significant difference between the observed and expected number of cases (2=1.70; p=0.89), 
supporting the high predictive value of the three biomarkers. Receiver operating characteristic 
(ROC) curve for the discriminatory power of these biomarkers is demonstrated in Figure 7. 
(AUC 0.94; 95% CI: 0.88-0.99). 
 
Combinations 
of biomarkers  
EGFR†   
  
Chromogranine   
A* 
P53‡       DAP risk 
1 - - - 0.0691 
2 + - - 0.4553 
3 - + - 0.4620 
4 - - + 0.6074 
5 + + - 0.9062 
6 + - + 0.9457 
7 - + + 0.9470 
8 + + + 0.9951 
*Chromogranine A: - for negative or <4 cells; + for ≥5 cells 
†EGFR: - for negative /<10% membrane staining/≥ 10% incomplete membrane 
staining; + for ≥10% weak, moderate/strong membrane staining 
‡p53 percentage: - for negative/≤9%; + for ≥10% 
 
Table 5. The predictive value of the three selected biomarkers in 24 preoperative core biopsy cases. 
 
Note: Since these 24 preoperative core biopsy cases may have a different baseline risk compared to the 
remaining 86 cases, the baseline risk should be adjusted. The risk of DAP was 50% (12/24) in the 
preoperative dataset, which was higher than the risk of 11.8% (13/110) in the trained dataset. The 
adjustment is described as follows. The predictive probability of being DAP in the trained dataset (110 
samples) was 
e
1 e
4.8883 2.4476 2.4208 3.0364 53
Score
Score
P
Score Chra EGFR p
  
               
Given the fact that the frequencies of positive results on Chromogranine A, EGFR, and p53 in the 
validated dataset are 37.5%, 12.5%, and 45.8%, respectively, substituting these figures into the 
equation with the probability equal to 0.5 yielded the adjusted intercept of -2.6, which replaces the 
figure of -4.8883.   
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Figure 7. Receiver operating characteristic (ROC) curve for the discriminatory power of the combined 
biomarkers Chromogranin A, EGFR and p53 percentage 
 
4.3 Prediction of ECE 
 
Overall, of the 168 sides analysed, none of the three / four cores contained tumour tissue in 39 
cases (23.2 %), only one of three / four in 67 cases (39.8%), two of three / four in 39 cases 
(23.2 %), and three of three / four biopsies were positive in 23 cases (13.6 %), respectively. 
Analysis of the 168 prostate sides revealed a significant association between the number of 
positive needle cores per side and the histopathologic finding of ECE (p = 0.0003). 
Specifically, when 0 to 1 needle core contained tumour tissue, ECE was detected in only 5.1% 
and 13.4% of prostate sides, respectively. Conversely, when two or three of three / four needle 
cores were positive ECE was detected in 35.8% and 65.2% of sides, respectively (Figure 8). 
Receiver operating Characteristic Curve for Hisological 
Type by Chromogranine A, EGFR and p53 percentage 
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Figure 8. Side-for-side (168 sides) analysis of at least sextant biopsies showing a significant 
association (p=0.0003) between the number of positive biopsy cores per side and the finding of ECE at 
RP. 
 
 
A dominant-side analysis of the same subset of patients again demonstrated a significant 
association between the number of positive sextant or octant biopsy cores and the presence of 
ECE (Figure 9). ECE was seen in only 5.7% of the sides that preoperatively had one needle 
core biopsy specimen positive for tumour. In contrast, ECE was seen in 20.6% and 60% of 
sides that had two or three tumour-positive needle cores preoperatively (p = 0.008). 
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Figure 9. Dominant side (84 sides) analysis demonstrating an association (p=0.008) between the 
number of positive biopsy cores per side and finding of ECE at RP. 
 
 
To calculate sensitivity, specificity and positive and negative predictive values, it was 
necessary to define a cut-off value for positive and negative test results for systematic needle 
biopsy data. As our data indicated that patients with prostate sides containing no or one core 
positive out of the three or four available were at significantly lower risk of extracapsular 
disease than those containing two or three positive cores, the finding of no or only one 
tumour-positive needle cores was defined as a negative test result for ECE. Conversely, as the 
risk of having ECE in patients with prostate sides giving two or three tumour-positive needle 
cores was several times higher, this finding was used to indicate a positive test result. 
Analysis of the 168 prostate sides revealed that systematic needle biopsies had a positive 
predictive value of 46.7% and negative predictive value of 89% (Table 6). 
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No ECE 
 
ECE 
0-1 positive biopsy cores  95 11 
2-3 positive biopsy cores 33 29 
Specificity: 74% 
Sensitivity: 72.5% 
Negative Predictive Value: 89% 
Positive Predictive Value: 46.7% 
 
Table 6. Results of the side-for-side analysis in predicting ECE 
 
Dominant-side (84 sides) analysis test results are shown in Table 7. In this case the positive 
and the negative predictive values were 37% and 94%, respectively. 
 
 
 
No ECE ECE 
1 positive biopsy core 33 2 
2-3 positive biopsy cores 31 18 
Specificity:  51% 
Sensitivity:  90% 
Negative Predictive Value:  94% 
Positive Predictive Value:  37% 
 
Table 7. Results of the dominant side analysis in predicting ECE 
 
Figure 10 illustrates the presence or absence of ECE in relation to PSA levels, while Figure 
11 shows its relation to the Gleason score. Presence of ECE in relation to the combination of 
the three analysed parameters (number of positive biopsy cores, preoperative PSA level and 
biopsy Gleason score) is presented in Figure 12.     
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Figure 10. Relationship between the preoperative PSA level and the presence of ECE at RP 
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Figure 11. Relationship between the biopsy Gleason score and the presence of ECE at RP 
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Figure 12. Relationship between the combination of three prognostic parameters (number of positive 
biopsies, preoperative PSA level and biopsy Gleason score) and the presence of ECE at RP. The high-
risk parameters are: number of positive biopsies >1; Gleason score 7 or more; serum PSA > 10 ng/ml. 
 
 
 
 
5. DISCUSSION  
 
 
DAP was initially described in 1967 as “endometrial carcinoma” because of its histological 
resemblance to endometrial carcinoma and presumed origin from the verumontanum, a 
Mullerian structure (42). The initial impression in the pathology literature was that of a truly 
endometrial tumour arising in a vestigial Mullerian structure. However, subsequent reports on 
favourable response to orchiectomy (43) and immunohistochemistry (21,44,45) have proven 
that it is a neoplasm of prostatic origin. Consequently, the term endometrial adenocarcinoma 
of the prostate is no longer justified. 
The most important original articles on DAP are summarized in Table 8. 
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References Country Type of 
the study 
Study 
Period 
No. of 
DAP 
 
Most important message of study 
1. 
Walker et al, 
1982 (44) 
USA Case 
report 
1982 1 The immunohistochemical findings and the close association of the 
adenocarcinoma with the prostatic epithelium of the villous polyp provided 
evidence that so-called endometrial carcinoma of the prostatic utricle is of 
prostatic epithelial origin rather than of Mullerian derivation. 
 
2. 
Bostwick et 
al, 1985 (45) 
USA Histo. 1968-
1982 
13 They agree with the suggestion of Walker et al (44) that the term 
„endometrial” should be abandoned. They prefer to classify these as prostatic 
adenocarcinomas with endometrioid features. These tumours are clinically 
more aggressive than previously thought. 
3.          
Epstein et al, 
1986 (21) 
USA Histo. 1963-
1983 
10 They supports the concept of Bostwick et al (45) and Walker et al (44) that 
prostatic carcinomas with endometrioid features is a morphologic variant of 
DAP. These tumours have not shown Mullerian nature.   
4.  
Christensen 
et al 1991(23) 
USA Histo. 1986-
1989 
15 with 
RP 
DAP-s are in advanced pathologic stage by the time of presentation and have 
a much higher short-term failure rate after RP than AAP. 
5.  
Millar et al, 
1996 (46) 
UK Histo. 1979-
1996 
16 Patients with DAP had shown good response to hormone therapy and these 
tumours had a relatively good prognosis. 
6.  
Oxley et al, 
1998 (47) 
UK Immuno-
histo. 
1982-
1996 
12          
6 pure    
6 mixed 
The percentage of tumours expressing p53 was similar to the percentage 
published for high grade AAP. The results for Ki-67 suggest that DAP have 
higher scores than AAP. 
7.  
Bock et al, 
1999 (25) 
USA Histo. 1992-
1994 
17 The only specific feature for DAP is its distinctive site of growth. Papillary and 
cribriform growth of cancer on needle biopsy should not be considered 
diagnostic. They recommended to reject the diagnosis of DAP. 
8.  
Brinker et al, 
1999 (22) 
USA Histo. -1998 58 They conclude that DAP seen on needle biopsy implies more advanced 
cancer with shortened time to progression. 
 
9.  
Tu et al, 2002 
(48) 
USA Clinical 1977-
1997 
12         PCa patients with penile or testicular metastases have unique clinical and 
pathological characteristics. Many of these tumours are compatible with a 
subtype of DAP. 
10. 
 Orihuela et 
al, 2008 (49) 
USA Clinical 1990-
2005 
17   Contemporary management of localized DAP with radiation and endocrine 
therapy yields adequate disease free survival. Patients with metastatic DAP 
respond well to endocrine treatment.    
11.  
Tavora et al, 
2008 (50) 
USA Clinical/his
to. 
1999-
2007 
28 PIN-
like 
PIN-like DAP behaved similar to Gleason score 6 AAP. 
12.  
Lotan et al, 
2009 (51) 
USA Mol. 
Pathol. 
1984-
2005 
38 Significantly lower rate of the TMPRSS2-ERG gene fusion in pure DAP 
compared to AAP indicating a genetic and biologic difference between the 
two tumour types. 
13.  
Tu et al 2009 
(52) 
USA  Clinical/his
to. 
1985-
2006 
75 with 
RP 
They evaluated 50 mixed and 25 pure DAP. Pure DAP had better prognosis 
than mixed type of DAP.  
 
14.  
Lee et al, 
2010 (53) 
USA Histo. 1987-
2009 
10 They reported 10 unique histological patterns of DAP and showed the 
differential diagnostic difficulties of these tumours.  
 
15.  
Morgan et al, 
2010 (54) 
USA Clinical 1996-
2006 
371  
(0,1%) 
Patents with DAP diagnosis are more likely to present with advanced stage 
cancer. Men with nondistant disease at diagnosis of DAP had 2.2-fold 
increase in disease specific mortality.     
16. 
Samaratunga 
et al, 2010 
(19) 
Australi
a 
Histo. 2004 34 
(12,7%) 
Twenty-five cases (73%) with DAP had ECE compared to 32.9% of AAP 
cases. They recommended that any portion of ductal component should be 
reported in core biopsies specimens. 
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Table 8. Survey of DAP related literature from PubMed including papers published between 1982 – 
2011. 
 
 
DAP, as we have defined it, comprised 11.8% of all tumours in our study, which was based 
on an unselected consecutive series of 110 patients who underwent RP. This proportion is 
somewhat higher than the proportion of DAP reported in most previous studies 
(23,45,46,53,54) although a higher percentage has also been reported (19). We attribute the 
higher frequency of DAP in our material to the use of subgross (3D) histology in all 110 total 
prostatectomy samples, because this technique provides better visualization of ductal 
structures, particularly at the periphery of the prostate, where 12/13 of the DAP tumours were 
found in our material.   
 
There are many differential diagnostic difficulties when diagnosing DAP on needle biopsies. 
The most difficult distinction is between cribriform high-grade PIN and DAP. There are 
several features that may distinguish these two lesions on needle biopsy. DAP often contain 
true papillary fronds with well-established fibrovascular cores, whereas PIN more frequently 
shows micropapillary fronds with tall columns of epithelium without fibrovascular stalks. 
DAP may show stromal fibrosis, haemosiderin deposition or perineural invasion, which 
would not be seen with PIN. Finally, DAP may consist of very large or back-to-back glands, 
whereas glands involved by PIN are of the size and distribution of benign glands. We agree 
with the suggestion of Brinker et al that many of the cases that have been designated as 
intaductal carcinomas earlier would be now regarded as DAP. Pathologist must be able to 
17. 
 Amin et al, 
2011 (20) 
 
 
 
 
USA Histo. 1995-
2008 
93 
(0,5%) 
DAP admixed with Gleason grade 3 is more aggressive than Gleason score 7 
AAP, as long as the ductal component is => 10%. Gleason score 8-10 
tumours with ductal features are not significantly more aggressive than AAP 
Gleason score 8-10 cancers. 
18.  
Finamanti et 
al, 2011 (55) 
Italy Clinical 1997-
2010 
56 
(4,5%) 
DAP is more likely to present with advanced clinical stage at diagnosis than 
AAP 
 
19.  
Meek et al, 
2011 (56) 
USA Clinical 1970-
2011 
693 
(~0,1%) 
DAP is associated with a high rate of PCa specific mortality, similar to 
Gleason 4+4 AAP. 
 
20.  
Our study 
2012 
Sweden Immuno-
histo. 
2000-
2006 
13  
(11,8%) 
Assessment of chromogranine A, p53, and EGFR in prostate carcinoma may 
serve as useful adjunctive diagnostic tools for delineating more aggressive 
prostate cancer cases exhibiting ductal differentiation.  
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recognize this morphology as being malignant on needle biopsy regardless of the presence of 
basal cells (22).  
 
Several recent publications indicated a more aggressive clinical course in cases with DAP 
compared to AAP, in contrast to occasional reports showing no difference between the two 
(46). A poor 5-year-survival rate, ranging from 15% to 43% was reported by Bostwick et al 
(45), Christensen et al. (23), Morgan et al. (54) and Samaratunga et al. (19). In the present 
study, factors that are related to poor prognosis, i.e. tumour stage, high grade PIN, Gleason 
score, positive surgical margins, ECE, vascular invasion and seminal vesicle infiltration were 
associated with tumours showing ductal differentiation. As much as 25% to 40% of patients 
with DAP have metastases at the time of diagnosis (52). In addition, these tumours tend to 
spread to unusual sites, such as the penis, testis, visceral organs (liver, lungs, brain) and skin 
(48,57,58). Our results also indicate an unfavourable prognosis in cases showing ductal 
differentiation; visceral metastasis (1 case), skeletal metastases (2 cases), locoregional lymph 
node metastases (2 cases), and prostate cancer related death (1 case) were seen exclusively in 
tumours with ductal differentiation in this study. While some authors indicate that ductal 
differentiation in less than 10% of the tumour has no prognostic relevance (20), others, 
similarly to our study, provided evidence to the contrary (19).  
 
Although there are sporadic reports on DAP exhibiting bcl-2 (59) or CK20 (26) in contrast to 
AAP, we did not find any systematic studies in the literature regarding specific 
immunohistological marker panel(s) that would reliably distinguish between DAP and AAP. 
Therefore, we designed the present study to test commercially available, routinely used 
antibodies in this setting. We found p53, chromogranine A, EGFR and Ki-67 expression of 
the tumour cells to be associated with ductal differentiation, and therefore as promising 
potential immunohistochemical markers of this phenotype. 
 
The prostate gland has the largest population of neuroendocrine cells in the male genital tract. 
Some authors found a correlation between NED in PCa and Gleason score and/or other 
factors indicating aggressive behaviour (60). 
An increased number of neuroendocrine cells have been reported in advanced tumour stages, 
high-grade versus low-grade tumours, and especially after patients were treated with androgen 
suppression (29-31). In contrast, other researchers found no correlation (61). In theory, 
tumours derived from a more mature progenitor cell in the stem-cell hierarchy tend to be 
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homogeneous and express a monoclonal phenotype, whereas tumours derived from an earlier 
(more pluripotent) progenitor cell tend to be heterogeneous and exhibit a more mixed 
phenotype (62). This may explain the presence of NED in some less differentiated PCa, and 
the association of this differentiation with DAP.  
 
The p53 protein induces cell-cycle arrest at the G1 and G2 checkpoints prior to DNA 
replication and allows the repair of damaged DNA, but also allows the induction of apoptosis. 
Mutations in the TP53 gene, resulting in loss of the tumour-suppressing functions of wild type 
(normal) p53 and gain of oncogenic functions are frequently found in invasive cancers, 
including PCa. Mutations in the TP53 gene are considered a late event in prostate 
carcinogenesis, and it is unclear whether wild type p53 is expressed in significant amounts in 
early-stage cancer. Nuclear positivity for p53 in PCa is associated with higher grade tumours, 
advanced tumour stages, and predicts a poor prognosis (63), an association which was also 
found in the present study.  
 
EGFR is a membrane-associated tyrosine kinase, and its activity is regulated by ligand-
binding and by interactions with receptors of the EGFR family (64). Once this molecule is 
phosphorylated, the activated signal is passed down through signaling cascades, activating 
numerous downstream molecules, what ultimately affects cell division, proliferation and cell 
migration (64). Abnormal signaling in EGFR-related pathways leads to uncontrolled cell 
growth and has been reported in many solid tumours such as breast, colorectal, head and neck 
and pancreatic cancers (64).  
The molecular mechanisms responsible for PCa development, progression and hormone-
independence are not clear yet. Several findings suggest that alterations of different pathways 
involving growth factor receptors play a role in this multistep process (65). In particular, 
EGFR is frequently overexpressed in PCa and this is associated with a more aggressive 
clinical outcome. EGFR is down regulated at the transcriptional level by androgens in normal 
prostate tissue but up regulated in prostate malignancy, especially in androgen-independent 
PCa. EGFR overexpression has also been linked to the transition from androgen-
responsiveness to the androgen-independent/hormone-refractory phenotype (66). Di Lorenzo 
et al. have evaluated by immunohistochemistry the expression of EGFR in three different 
groups of PCa patients representative of different clinical stages of PCa. EGFR was evaluated 
as potential prognostic indicator of disease progression. A significant increase in EGFR 
expression was observed from patients treated with radical surgery alone and not yet exposed 
  
44 
 
to hormonotherapy (41.4%), to patients who received hormonotherapy as primary therapy 
before radical prostatectomy (75.9%), and finally to patients with metastatic and hormone-
refractory disease (100%) (67). Weber et al. have observed a significant association between 
EGFR expression and higher Gleason scores and poor outcome (68). It remains to be 
demonstrated if EGFR therapeutic targeting may optimize patient outcome (69).  
 
Ki-67 is a nonhistone protein that identifies proliferating cells. Ki-67 expression has been 
considered accurate in fresh-frozen tissue. MIB-1 antibody reacts with parts of the Ki-67 
antigen and is expressed in paraffin-embedded specimens. MIB-1 expression is similar to that 
of Ki-67 and is therefore recommended in paraffin-embedded specimens. Some recent studies 
of patients treated with RP have revealed a positive correlation between Ki-67 expression and 
cancer recurrence (70). 
The prognostic value of MIB-1 staining on paraffin embedded tissue after radical 
prostatectomy is, however, still controversial. While some authors have reported a correlation 
with poor prognosis (71-73), others did not (74,75), but it seems that MIB-1 expression is an 
independent marker of poor prognosis in the majority of the studies. Interestingly, expression 
of Ki-67 was less significantly different in the DAP and AAP in our study and therefore it was 
not within the first three selected biomarkers. 
 
A thorough statistical analysis demonstrated that a combination of chromogranine A, p53 and 
EGFR expression were reliable predictors of the presence of the ductal/mixed ductal-acinar 
type PCa in our series of prostatectomy specimens and remained reliable in the preoperative 
core biopsy series. Although these results are sound, larger studies are needed to confirm the 
discriminatory power of these biomarkers. 
 
 
Accurate preoperative prediction of the status of surgical margins is of paramount clinical 
importance for treatment planning, especially for patients being considered for nerve-sparing 
procedures and/or preoperative neoadjuvant therapy. Paulson et al (76,77) reported that 
positive margins were associated with decreased cancer specific and overall survival. The 
cumulative data suggest that surgical margin status is an important predictor of outcome, 
which in turn means that the ability for preoperative prediction of ECE has important clinical 
implications.  
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To our knowledge, Gancarczky et al`s study (17) represents the largest series of data 
demonstrating that the percentage of biopsy cores containing carcinoma (number of positive 
cores per total number of cores taken) is a highly significant independent predictor of ECE at 
the time of RP. In this study of 1510 patients from the Center for Prostate Disease Research 
database using univariate and multivariate analyses, pre-treatment PSA, biopsy Gleason score 
and the percentage of positive biopsy cores were the three most significant pre-treatment 
parameters predicting the margin status at radical prostatectomy, similar to other previous 
reports (15,16,78-82).  
Tigrani at al (83) studied 108 patients who underwent prostatectomy for PCa and found that 
the number of positive biopsies was the best predictor of margin status. It is not surprising, as 
it is known that serum PSA can be higher in simple hyperplasia of the prostate than in cases 
of malignancy. Serum PSA level is more important for diagnosing PCa and for the follow-up 
of the patients than for predicting the surgical margin status. However, in our study there was 
certain association between increased preoperative PSA levels and the presence of ECE at 
radical prostatectomy (see below).  
On the other hand, the discordance between the biopsy Gleason score and final Gleason score 
is well documented (84). Our study also revealed that this discrepancy can be diminished by 
increasing the number of preoperative biopsies. In cases of sextant biopsies the association 
with final pathological Gleason score was only 57.6%, while it reached 79.2% in octant 
biopsies.  
Our study showed that transrectal ultrasound-guided systematic at least sextant biopsies can 
be useful in stratifying patients according to the preoperative risk of ECE. In our study 
population, the prostate sides that demonstrated two or three positive needle biopsies were at 
several times higher risk of having ECE than those with no or only one positive core. 
Our results calculated for systematic sextant needle biopsies and demonstrated in Table 6 and 
7, indicate that this test has serious limitations when predicting ECE. Using the finding of two 
or three tumour-positive biopsy cores out of three (or four) cores taken per side as indicative 
of extracapsular disease shows a disappointingly low positive predictive value of only 37% 
and 46.7%, respectively. However, finding no or only one core sample to be positive for 
tumour accurately predicted the absence of extracapsular disease with a negative predictive 
value approaching 89% and 94%, respectively. 
Recently, wide consensus has been reached upon the role of well-determined Gleason score 
being a powerful prognostic factor for predicting pathologic stage, biochemical failure, local 
recurrences and lymph node or distant metastases at RP (14,17,85). It also correlates with 
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virtually all other adverse pathologic parameters, including tumour volume and inked margin 
status in radical prostatectomy specimens, serum PSA levels and many molecular markers. 
Specifically, high Gleason scores (7 or more) are associated with worse prognosis, and 
Gleason scores 5-6 are usually associated with lower progression rates after definitive therapy 
(85). In our study, positive association between biopsy Gleason score and the presence of 
ECE at RP could be demonstrated.  
The predictive value of the Gleason score is enhanced when combined with other clinical 
parameters, including rectal digital examinations and serum PSA levels (14,85). 
Furthermore, nomograms have been developed to predict the pathological stage at radical 
prostatectomy, and disease progression after surgery or radiation therapy. The nomograms 
typically include pre-treatment variables as clinical stage, biopsy-based Gleason score, serum 
PSA, amount of cancer in needle biopsies, etc. In Sweden, based on three prognostic 
parameters the patients are divided into low, moderate and high risk groups (Table 9) (86).  
 
 
Table 9. Risk groups of prostate cancer, based on the correlation between preoperative diagnostic 
parameters and 10-year cancer-free survival after RP according to D`Amico (87). 
 
 
This risk allocation predicts life expectancy and is important for treatment planning. Recently, 
an increasing number of clinicians have started to require more pathological information (e.g. 
the number of positive biopsies, percentage of cancer tissue in all biopsies) for their 
therapeutic decisions. Nomograms are used with increasing frequency in clinical practice by 
urologists and radiation oncologists to counsel their patients regarding therapeutic options and 
the potential risk of failure based on the therapy they choose (14,17,88). 
 The best-known algorithm to predict the pathologic stage of clinically localized prostate 
cancer is the Hamburg algorithm. This system categorizes patients into three risk groups for 
lymph node metastases based on the Gleason grade of a systematic sextant biopsy using 
classification and regression tree analysis (89,90). Because of the anatomic location of the 
Risk group Preoperative 
T category 
PSA ng/ml Gleason 
score 
10 years 
cancer free  
over living % 
Low  T1c-T2a and <=10 and <=6 83 
Intermediate T2b or 10-20 or 7 46 
High >=T2c or >20 or >=8 29 
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prostate gland, determination of the lymph node status is not easy. This is only possible with 
certain radiologic imaging techniques which have lower specificity and are more expensive 
than histological examination.  In other organs such as the breasts, we can get an accurate 
picture of the lymph node status with the examination of the sentinel lymph nodes (91-97).  
Although sentinel lymphadenectomy has been pioneered in prostate cancer too and has been 
described as feasible and potentially allowing unexpected lymphatic drainage and metastatic 
spread to be discovered (98,99), it has not gained wide acceptance. Briganti et al analysed 
corresponding prostate biopsy specimens with 278 consecutive prostatectomy specimens that 
included lymph node dissection (100). These authors concluded that the percentage of 
positive cores and biopsy Gleason score are the two most informative predictors of a positive 
lymph node status. They created a preoperative nomogram which had 83% accuracy for 
predicting lymph node status. The Briganti nomogram was recently validated by Heidenreich 
et al, who examined 499 biopsy-prostatectomy pairs and concluded that the percentage of 
positive cores was the most reliable predictor of lymph node metastases (101).  
 
Our results also indicate that combining the number of positive cores with additional 
parameters as preoperative PSA level and biopsy Gleason score further improves the 
prediction of ECE. Preoperative PSA levels <10 ng/ml in addition to Gleason score <7 and 
presence of cancer in no more than one core identified a low-risk patient group with no ECE 
observed in the present study. The opposite combination (preoperative PSA levels >=10 
ng/ml in addition to Gleason score >=7 and presence of cancer in more than one core) 
identified a group of patients with high risk (77% probability, 10/13) of ECE. These results 
strongly support that the combination of the above mentioned parameters might be used in 
therapeutical decision making.  
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6. SUMMARY, CONCLUSIONS  
 
6.1 Our results confirm the previous observations that tumours with ductal differentiation are 
associated with adverse prognostic variables and outcome.  
 
6.2 Our detailed immunohistochemical study demonstrated that the expression of p53, 
chromogranine A and EGFR in tumour cells of prostate cancer can differentiate tumours 
showing ductal differentiation from purely acinar cancers with reasonable accuracy. 
Assessing the expression of these biomarkers may represent not only useful ancillary 
diagnostic tools in prostate pathology, but could also predict a less favourable outcome.  
 
6.3 Both 3-dimensional histology and the three selected biomarkers (combining 
chromogranine A, EGFR and p53) can help to accurately distinguish DAP from AAP. This 
discriminatory ability offers AAP cases less radical treatment regimens and emphasizes the 
need to develop more effective treatment regimens for DAP cases.  
 
6.4 The results of the present study indicate that transrectal ultrasound-guided systematic, at 
least sextant needle biopsies can be used to assist the prediction of extracapsular disease at 
radical prostatectomy. Prostate sides giving no or only one PCa containing cores out of the 
three (sextant biopsy) or four (octant biopsy) are at a relatively low risk of having ECE 
compared with those containing two or three positive cores. Finding no more than one 
positive out of three or four cores available per side predicted the absence of extracapsular 
disease with a negative predictive value approaching 94%.  
 
 
6.5 Combining this information (see above under 6.4) with preoperative PSA level and biopsy 
Gleason score further enhances the predictive power for ECE. Such information is useful in 
planning nerve-preservation at RP.  
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